Phaseline

Companies › Zhejiang Vimgreen Pharmaceuticals

Zhejiang Vimgreen Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VG081821AC
Adenosine A2A receptor antagonist
ADORA2APhase 2Parkinson Disease (PD)Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07725562VG081821ACPhase 2Parkinson Disease (PD)NeurologyOct 2027

Targets

ADORA2A (1)

Companies with the same targets

Arcus Biosciences TJ Biopharma Gilead Sciences RDC Clinical iTeos Therapeutics GE Healthcare Innolake Biopharm AstraZeneca

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.